• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Lost jobs, Flat BRICs, Diabetes infections, DePuy’s former CEO, Urologix and Medtronic’s prostate pact, FDA reviewer training GI Dynamics’ first days on the market made headlines this week | MassDevice.com +7

Lost jobs, Flat BRICs, Diabetes infections, DePuy’s former CEO, Urologix and Medtronic’s prostate pact, FDA reviewer training GI Dynamics’ first days on the market made headlines this week | MassDevice.com +7

September 11, 2011 By MassDevice staff

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you’re still in the know with Massdevice +7.

7. GI Dynamics sinks 13 percent on opening day

GI Dynamics

GI Dynamics (ASX:GID) had a less-than-auspicious début on the Australian stock exchange yesterday, where GID share prices dropped 13 percent in their first day of public trading.

Read the full story.

Sign up to get our free newsletters delivered right to your inbox.

6. Device training for FDA reviewers

FDA

The FDA launches its reviewer certification program to tighten device application times as Congress prepares to dig deeper into the watchdog agency’s med-tech review process.

Read the full story.

5. Urologix, Medtronic ink prostate pact

Urologix
Medtronic

Urologix Inc. (NSDQ:ULGX) strikes a 10-deal with Medtronic (NYSE:MDT) to offer the Prostiva RF treatment, planning to couple that bladder obstruction treatment with its own Cooled ThermoTherapy system for patients with benign prostatic hyperplasia.

Read the full story.

4. Former DePuy Orthopaedics CEO Floyd lands on his feet

David FLoyd

David Floyd, the former CEO of DePuy Orthopaedics, starts a new gig today: CEO of OrthoWorx, an “industry, community and education initiative” that aims to boost the orthopedics cluster centered in Warsaw, Ind., according to its website.

Read the full story.

3. Diabetes device-related infections worry CDC

Fingerstick procedure

The number of patients exposed to blood-borne infections during diabetes testing, glucose monitoring and insulin delivery in group settings is on the rise, according to the Centers for Disease Control & Prevention.

Read the full story.

2. The BRIC bubble might be in for a flatline

BRIC markets

The predicted flat 7.9 percent growth for the BRIC nations of Brazil, Russia, India and China through 2012 could be bad news for the clutch of med-tech titans who have just committed big bucks on the growth of emerging markets.

Read the full story.

1. AdvaMed warns of 400,000 lost jobs on FDA’s excise tax

Capitol Hill

Medical device industry lobby AdvaMed says that the new 2.3 percent excise tax, slated to go into effect in 2013, will be "the last straw on the camel’s back" for medical device companies trying to thrive in the struggling American economy. 

Read the full story.

Filed Under: Food & Drug Administration (FDA), News Well, Wall Street Beat Tagged With: 510(k) reforms, AdvaMed, depuysynthes, GI Dynamics, Johnson and Johnson, Personnel Moves, Prostate, Urologix Inc.

More recent news

  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire
  • Medtronic wins CE mark for LigaSure sealing tech for Hugo surgical robot

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy